专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011151252A2 MEANS AND METHODS FOR DIAGNOSING PANCREATIC CANCER IN A SUBJECT 审中-公开
标题翻译：用于诊断主体中胰腺癌的手段和方法
公开(公告)号：WO2011151252A2
公开(公告)日：2011-12-08
申请号：PCT/EP2011/058670
申请日：2011-05-26
申请人： METANOMICS HEALTH GMBH , UNIKLINIKUM SCHLESWIG-HOLSTEIN , ERNST-MORITZ-ARNDT UNIVERSITÄT , KAMLAGE, Beate , RESZKA, Regina , KLUTTIG, Martin , KALTHOFF, Holger , SCHNIEWIND, Bodo , MEYERLE, Julia , LERCH, Markus
发明人： KAMLAGE, Beate , RESZKA, Regina , KLUTTIG, Martin , KALTHOFF, Holger , SCHNIEWIND, Bodo , MEYERLE, Julia , LERCH, Markus
IPC分类号： G01N33/574
CPC分类号： G01N33/574 , G01N33/57438
摘要： The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing pancreatic cancer in a subject, a method for identifying whether a subject is in need for a therapy of pancreatic cancer or a method for determining whether a pancreatic cancer therapy is successful. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.
摘要翻译：本发明涉及诊断方法领域。具体地，本发明考虑了用于诊断受试者中胰腺癌的方法，用于鉴定受试者是否需要胰腺癌治疗的方法或者确定胰腺癌治疗是否成功的方法。本发明还涉及用于执行上述方法的工具，例如诊断装置。

2. 发明申请

WO2016207391A1 MEANS AND METHODS FOR DIAGNOSING PANCREATIC CANCER IN A SUBJECT BASED ON A BIOMARKER PANEL 审中-公开
标题翻译：用于诊断基于生物标记物面板的主体中的胰腺癌的手段和方法
公开(公告)号：WO2016207391A1
公开(公告)日：2016-12-29
申请号：PCT/EP2016/064736
申请日：2016-06-24
申请人： METANOMICS HEALTH GMBH
发明人： KAMLAGE, Beate , RESZKA, Regina , SCHATZ, Philipp , DOSTLER, Martin , CARVALHO, Susan , PETER, Erik , MAPPES, Philipp , KALTHOFF, Holger , SCHNIEWIND, Bodo , MAYERLE, Julia , LERCH, Markus , GRUETZMANN, Robert , PILARSKY, Christian
IPC分类号： G01N33/574 , G01N33/68
CPC分类号： G01N33/57438 , G01N33/6806 , G01N33/6812 , G01N2405/08 , G01N2800/60 , G01N2800/7028 , G01N2800/7076 , G01N2800/7085
摘要： The present invention relates to a method for diagnosing pancreatic cancer in a subject comprising the steps of: (a) determining in at least one sample of said subject the amounts of a group of diagnostic biomarkers comprising (i) at least one diagnostic amino acid, said diagnostic amino acid being proline, histidine or tryptophan, preferably, being proline; (ii) at least one diagnostic ceramide, said diagnostic ceramide being ceramide (d18:1,C24:0) or ceramide (d18:2,C24:0), preferably being ceramide (d18:1,C24:0); (iii) at least one diagnostic sphingomyelin, said diagnostic sphingomyelin being sphingomyelin (35:1), sphingomyelin (d17:1,C16:0), sphingomyelin (41 :2) or sphingomyelin (d18:2,C17:0), preferably being sphingomyelin (35:1); and (iv) CA19-9; and (b) comparing said amounts of the diagnostic biomarkers with a reference, whereby pancreatic cancer is diagnosed. Moreover, the present invention relates to a method for determining the probability for a subject to suffer from pancreatic cancer, and to devices and uses related to said methods.
摘要翻译：本发明涉及一种用于诊断受试者的胰腺癌的方法，包括以下步骤：（a）在所述受试者的至少一个样品中测定一组诊断性生物标志物的量，所述诊断生物标志物组包含（i）至少一种诊断性氨基酸，所述诊断性氨基酸为脯氨酸，组氨酸或色氨酸，优选为脯氨酸; （ii）至少一种诊断性神经酰胺，所述诊断性神经酰胺为神经酰胺（d18：1，C24：0）或神经酰胺（d18：2，C24：0），优选为神经酰胺（d18：1，C24：0）; （iii）至少一种诊断性鞘磷脂，所述诊断性鞘磷脂是鞘磷脂（35:1），鞘磷脂（d17：1，C16：0），鞘磷脂（41：2）或鞘磷脂（d18：2，C17：0）是鞘磷脂（35：1）; 和（iv）CA19-9; 和（b）将所述诊断生物标志物的量与参考文献进行比较，由此诊断胰腺癌。此外，本发明涉及一种用于确定受试者患有胰腺癌的可能性的方法以及与所述方法相关的装置和用途。

3. 发明申请

WO2015091962A1 MEANS AND METHODS FOR DIAGNOSING PANCREATIC CANCER IN A SUBJECT BASED ON A METABOLITE PANEL 审中-公开
标题翻译：用于诊断基于代谢物面板的主体中的胰腺癌的手段和方法
公开(公告)号：WO2015091962A1
公开(公告)日：2015-06-25
申请号：PCT/EP2014/078765
申请日：2014-12-19
申请人： METANOMICS HEALTH GMBH
发明人： KAMLAGE, Beate , RESZKA, Regina , PETER, Erik , KASTLER, Jürgen , SCHATZ, Philipp , KALTHOFF, Holger , SCHNIEWIND, Bodo , MAYERLE, Julia , LERCH, Markus , PILARSKY, Christian , GRÜTZMANN, Robert
IPC分类号： G01N33/574
CPC分类号： G01N33/57438 , G01N33/49 , G01N33/92 , G01N2400/00 , G01N2405/00 , G01N2405/04 , G01N2405/08
摘要： The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing pancreas cancer in a subject and, preferably for differentiating between pancreatic cancer and pancreatitis and a method for identifying whether a subject is in need for a therapy of pancreatic cancer. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.
摘要翻译：本发明涉及诊断方法领域。具体地，本发明考虑了用于诊断受试者中的胰腺癌的方法，优选用于胰腺癌和胰腺炎的分化以及用于鉴定受试者是否需要胰腺癌治疗的方法。本发明还涉及用于执行上述方法的工具，例如诊断装置。

4. 发明申请

WO2019121942A1 METHODS FOR DIAGNOSING PANCREATIC CANCER 审中-公开
公开(公告)号：WO2019121942A1
公开(公告)日：2019-06-27
申请号：PCT/EP2018/085882
申请日：2018-12-19
申请人： METANOMICS HEALTH GMBH , UNIVERSITAETSMEDIZIN GREIFSWALD
发明人： KAMLAGE, Beate , CHRISTIANSEN, Nicole , SCHATZ, Philipp , PILARSKY, Christian , GRUETZMANN, Robert , BAHRA, Marcus , MAYERLE, Julia , LERCH, Markus , CHROMIK, Ansgar Michael
IPC分类号： G01N33/574 , G01N33/68
CPC分类号： G01N33/57438 , G01N33/6812
摘要： The present invention relates to a method for diagnosing pancreatic cancer in a subject suspected to suffer from pancreatic cancer comprising the steps of: (a) determining in a sample of said subject the value of (i) at least one biomarker of the categories carnitines, amino acids, and mitochondrial energy metabolites, and (ii) a first and a second sphingolipid, wherein the fatty acid residue of the first sphingolipid is at least four carbon atoms longer than the fatty acid residue of the second sphingolipid, and wherein the sphingosine backbone of the first sphingolipid and the second sphingolipid are identical;and (b) comparing the values of the biomarkers with references, whereby pancreatic cancer is diagnosed; and to a method for identifying whether a subject is in need of a pancreatic cancer therapy related thereto. The present invention further relates to a device for diagnosing pancreatic cancer in a sample of a subject comprising (a) an analyzing unit for the sample of the subject comprising a detector for the amounts of at least one biomarker each of the categories carnitines, amino acids, energy metabolites, and sphingolipids; said detector allowing for the determination of the amounts of the biomarkers of the said group of biomarkers in the sample; and operatively linked thereto, (b) an evaluation unit comprising a data processing unit and a data base, said data base comprising a stored reference and said data processing unit having tangibly embedded an algorithm for carrying out a comparison of the amounts of the biomarkers of the group of biomarkers determined by the analyzing unit and the stored reference and for generating an output information based on which the diagnosis can be established. Further, the present invention relates to a data collection and too a use related to the aforesaid subject matter.

5. 发明申请

WO2019122342A1 METHOD FOR THE ASSESSMENT OF NAFLD 审中-公开
公开(公告)号：WO2019122342A1
公开(公告)日：2019-06-27
申请号：PCT/EP2018/086616
申请日：2018-12-21
申请人： METANOMICS HEALTH GMBH
发明人： SCHULZE-PELLENGAHR, Silke , WAGNER-GOLBS, Antje , REIN, Dietrich , SCHATZ, Philipp , CHRISTIANSEN, Nicole , BERG, Thomas , HAMPE, Jochen , DATZ, Christian , STICKEL, Felix , LERCH, Markus
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/085
摘要： The present invention relates to a method for assessing non-alcoholic fatty liver disease (NAFLD) com- prising determining in a sample from a subject suffering from NAFLD at least the amounts of two metabolite biomarkers, wherein said two metabolite biomarkers are: (i) at least one eicosatrienoic acid metabolite biomarker and (ii) at least one androgen metabolite biomarker and/or at least one bile acid metabolite biomarker. Further, the present invention relates to the vitro use of the at least two metabolite biomarkers for assessing non-alcoholic fatty liver disease (NAFLD).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式